K-Beauty in Japan: The Quasi-Drug Pathway for Indie Brands Selling Whitening or Anti-Aging (2026)
Japan is one of the few markets where an indie K-beauty brand can be technically ready to ship on paper and still be legally blocked at the border. The reason is not paperwork sluggishness. It is that Japan splits skincare into three regulatory tiers, and the tier your product falls into is decided by what you claim, not by what is inside the bottle.
If your Korean ODM formula is a hydrating serum with vague "glow" copy, you can enter Japan as a cosmetic on notification. If the same serum is marketed with a whitening or wrinkle-improvement claim, you have crossed into the quasi-drug tier and you now need a pre-market approval, an approved active on your label, and a licensed local partner willing to hold the marketing authorization. Founders often discover this after they have printed cartons.
This is a founder-facing walkthrough of the pathway Korean-made K-beauty products actually travel to reach Japanese consumers when the label promises whitening or wrinkle improvement. It is written for US indie brands weighing Japan as a second market and for founders whose Korean ODMs have already suggested Japan as a natural expansion.
The three-tier system: cosmetic, quasi-drug, pharmaceutical
Japan regulates topical products under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, known in shorthand as the PMD Act. The Ministry of Health, Labour and Welfare (MHLW) sets the rules; the Pharmaceuticals and Medical Devices Agency (PMDA) does the scientific review and inspection work. Everything topical is classified into cosmetics (化粧品), quasi-drugs (医薬部外品, iyakubugaihin), or drugs. The tier decides the paperwork, the timeline, and the cost of failure.
Cosmetics in Japan are products for cleansing, beautifying, or promoting attractiveness that act mildly on the body. They can be launched by pre-market notification to the local prefectural authority, provided the formula respects the ingredient rules described below. There is no pre-market efficacy review.
Quasi-drugs sit between cosmetics and drugs. They contain approved active ingredients at defined concentrations intended for a specific preventive or corrective purpose: preventing acne, preventing rough skin, whitening, anti-wrinkle improvement, deodorant, anti-dandruff, medicated lip care, and so on. A quasi-drug must be approved by MHLW before it is manufactured or imported, and the approval is granted product-by-product, not brand-by-brand.
Drugs are the pharmaceutical tier and are not the pathway indie beauty brands travel. Prescription retinoids, for example, live here. If a US indie brand is being told by a Korean ODM that a product must go the drug route, that is a signal to change the formula or the claim, not to push forward.
Which claims trip a K-beauty product into quasi-drug territory
The single most useful heuristic for a founder is this: the tier is set by the claim, not by the ingredient. A serum with alpha-arbutin can be a cosmetic in Japan. Add "whitens by suppressing melanin production" to the copy and it becomes a quasi-drug that requires a filed approval before it can ship. The same is true of niacinamide with a wrinkle-improvement claim, and of any language that promises to prevent acne, prevent rough skin, or prevent chapping.
Claim language matters at the level of specific wording. Japanese regulators evaluate a translated copy of the label, the outer carton, the product insert, and the promotional website copy. A brand that keeps its Japan-facing copy tight to cosmetic-tier language ("brightens the look of the skin," "smooths the appearance of fine lines") can stay in the cosmetic lane. A brand that uses the direct verbs ("whitens," "improves wrinkles") is filing quasi-drug paperwork.
The historical marker most founders should know: until 2017 no Japanese product had ever received quasi-drug approval for the specific claim "improves wrinkles." POLA cleared that bar first with a proprietary active ingredient after roughly fifteen years of development work, and Shiseido followed several months later with a retinol-based formulation. The wrinkle-improvement claim is not decorative. It is a scientific claim that requires a submitted dossier and MHLW sign-off, and the two brands that broke that ground built new active ingredients or ran clinical work to get there. That history is public and is worth reading before a founder assumes wrinkle language will be automatic in Japan.
What actually gets filed: notification vs. full quasi-drug application
Not every quasi-drug application requires clinical data. Quasi-drug approvals in Japan split into two rough tracks, and the track a K-beauty product travels depends on whether the active ingredient is already on MHLW's list of approved actives at the intended concentration and for the intended purpose.
The first track is a streamlined notification-style pathway for products that combine already-approved active ingredients at approved concentrations for approved purposes. If a Korean ODM has built the serum around, for example, tranexamic acid at a whitening-approved concentration and the rest of the formula complies with Japan's cosmetic ingredient standards, the filing burden is meaningfully lighter. There is still a dossier. There is still a review. But there is not a demand for new clinical work to prove the active does what it does.
The second track is a full application, and it is the track a product enters when the formula uses a novel active, a new combination of actives, a new concentration, or a new claim (the POLA-style "improves wrinkles" is the archetypal example). The dossier for this track is closer to a mini-pharmaceutical submission. It includes active and inactive ingredient lists with safety and quality justification, formulation and manufacturing process descriptions, non-clinical or clinical data supporting the claim, packaging and labeling design, and evidence of compliance with Good Quality Practice (GQP) and Good Vigilance Practice (GVP). Processing periods vary by data completeness, but the simpler application types generally require nine to twelve months, and applications built around novel actives can take longer.
PMDA has also flagged that from April 2026, the electronic Common Technical Document (eCTD) version 4.0 becomes mandatory for regulated submissions. That is more of an operational note than a strategic one, but it is worth knowing that the submission format itself is shifting.
Prerequisites: the licenses your Japan partner must hold before you can ship a single unit
Indie brands almost never hold Japanese licenses directly. The realistic structure for a US-headquartered K-beauty brand is to partner with a Japanese company that already holds the licenses and to route the product through them. That partner is doing three specific things.
The first is holding the Marketing Authorization Holder (MAH) license. Under the PMD Act, a Cosmetics Marketing Authorization Holder license is required to sell cosmetics in Japan; a corresponding license is required for quasi-drugs. The MAH takes on regulatory responsibility for product quality, post-market surveillance, and adverse event reporting. When something goes wrong in the Japanese market, the MAH is the accountable party in front of the authorities.
The second is holding an import business license. Selling and importing are separate licensed activities; a partner can hold both, but a founder should ask specifically. A distributor that can sell in Japan is not automatically permitted to import from abroad.
The third is Foreign Manufacturer Registration (FMR), which is a separate accreditation held by the Korean ODM factory rather than by the brand or the Japanese partner. Any overseas manufacturer that ships quasi-drugs or drugs into Japan must be registered with MHLW; PMDA examines the buildings and facilities of the manufacturing establishment as part of that process. FMR was previously called Foreign Manufacturer Accreditation (FMA) and older Korean ODM presentations still use the older acronym. If a Korean ODM cannot confirm that its facility is FMR-registered for quasi-drug output, the ODM is not ready for a Japan launch and neither is the brand. (This is the same kind of ODM-side due diligence a US indie brand should already be doing at home; our pre-PO due diligence checklist for Korean ODMs is a good place to start.)
Formulation gotchas: a Korean-approved formula is not a Japan-approved formula
Japan's ingredient rules are written in a way that is subtly different from Korea's, and a Korean ODM that has only shipped to KFDA-regulated markets will often miss the differences on the first pass.
MHLW's Standards for Cosmetics defines a short positive list for preservatives, UV absorbers, and tar colors with concentration ceilings, plus a negative list of prohibited substances and a separate restricted list of substances allowed only under defined conditions. (For a Korea/US/EU regulatory comparison, see our earlier walkthrough of KFDA vs FDA vs EU standards for K-beauty brands selling globally.) Everything else is permitted after the manufacturer verifies safety and appropriateness. That framing is looser than the EU's positive-list approach but tighter than a pure disclosure regime, and it produces real cases where a Korean formula that clears MFDS can still contain a preservative concentration or UV filter that Japan caps lower, or a tar color Japan does not accept for the intended product form. Those cases usually require a small reformulation on the Korean side before a Japanese cosmetic notification will hold up.
Labeling introduces its own layer. All cosmetics sold in Japan must carry Japanese-language labeling. The Japanese labeling must match the approved product record for a quasi-drug and must respect the notification for a cosmetic. Ingredient names must be listed using the Japanese Cosmetic Ingredient Names (JCID) system, which is not always a one-to-one mapping to INCI. That is a translation problem, but a translation problem with regulatory teeth.
I'm Liz, and I run altameet from Manhattan, NYC. Japan is a very tempting second market for a Korean-made brand. The retail infrastructure is there, the K-beauty aisle is already built, and shipping from Seoul is short. What usually surprises founders in our first conversation is how much the tier depends on the copy on the box, not the molecule in the bottle. If you want a fifteen-minute gut-check on whether your current formula and claims will make Japan a notification job or a nine-to-twelve-month quasi-drug filing, I will give you that. Book a slot with me at altameet.com/contact or write to liz@altameet.com.
A working timeline: what a Japan launch looks like from spec-sheet to shelf
The realistic sequencing for a Korean-made indie K-beauty product entering Japan as a cosmetic is measured in months, not weeks. First, the Korean ODM submits its facility for FMR if it is not already accredited. Second, the brand identifies and contracts a Japanese MAH partner. Third, the formula is re-vetted against the Standards for Cosmetics, and any preservative, UV filter, tar color, or restricted-ingredient issue is resolved with a reformulation or a concentration adjustment. Fourth, Japanese labeling is drafted, INCI names are mapped to JCID, and the label copy is validated against cosmetic-tier claims. Fifth, the MAH files the product notification. Sixth, the ODM manufactures and ships against confirmed purchase orders.
The quasi-drug pathway is longer by the length of the review itself. Straightforward filings that combine already-approved actives at approved concentrations tend to fall inside the nine-to-twelve-month PMDA processing window. Filings with novel actives or novel claims run longer, and applicants should budget for review questions and dossier revisions. A brand that wants a whitening or wrinkle claim in the Japan market should assume its Japan launch will trail its US launch by at least a full year and should plan its Japanese-language marketing calendar accordingly.
Six questions every K-beauty founder should ask before opening Japan
These questions surface most of the surprises founders run into in the first six weeks of Japan planning.
Does the Japan-facing claim keep the product in cosmetic-tier language? If yes, the pathway is notification. If no, the pathway is quasi-drug and every downstream cost and timeline number moves.
Is the Korean ODM's manufacturing site FMR-registered for the intended product tier? An ODM registered for cosmetic export may not be registered for quasi-drug export; the accreditation is granular.
Do the actives already sit on MHLW's approved list at the intended concentration and purpose? If yes, the quasi-drug pathway is a streamlined dossier. If no, the pathway is a full application with clinical or non-clinical support and a longer clock.
Does the current formula clear the positive lists and stay off the negative and restricted lists? Any preservative, UV filter, or tar color question needs to be answered before Japanese labeling is designed, not after.
Which Japanese MAH will hold the marketing authorization and adverse event reporting duties? This is a real contract with real ongoing obligations. Founders should ask what the MAH's post-market surveillance capacity looks like, not just what the setup fee is.
Who translates the label, and who signs off on the Japanese copy? The MAH usually leads this, but a brand should read every claim word-for-word in Japanese before signing off. Translation quality and regulatory language are not the same skill.
FAQ
Is my Korean ODM enough, or do I need a Japan-based ODM partner too? Your Korean ODM is enough for the manufacturing side if its facility is FMR-registered for the intended tier. What you additionally need on the Japan side is an MAH plus import business licensee, which is a regulatory and distribution partner, not a manufacturing partner.
Can a US LLC own the MAH in Japan? The MAH must be a licensed Japanese entity. A US LLC can incorporate a Japanese subsidiary and pursue the license itself, but for most indie brands the practical answer is to contract with an existing licensed local partner rather than build the entity.
My Korean-language whitening serum uses tranexamic acid. Can I ship it to Japan as a cosmetic? Only if the Japan-facing label and copy do not make a whitening claim. Tranexamic acid as a molecule is not the trigger; the whitening claim is. Some brands run a Japan version of their SKU with softer copy so the product can enter under the notification pathway.
How long does a quasi-drug approval actually take? Straightforward filings that combine already-approved actives at approved concentrations tend to fall inside the nine-to-twelve-month PMDA processing window. Novel-active or novel-claim filings often take longer and should not be planned as a cosmetic-timeline job.
Do I need clinical trials? Only if the active or the claim is novel to Japan. Reformulating around an already-approved active for an already-approved purpose keeps you in the streamlined pathway without new clinical work.
What is the failure mode I should worry about most? Shipping product before the Japanese label copy has been checked against the notified or approved record. Customs and post-market surveillance in Japan take label conformity seriously, and a mismatch between the label and the record is the most common reason a Japan launch stalls after inventory has already been sent.
Is Japan worth the trouble for a small indie K-beauty brand? It depends on where your marketing story lives. If your brand has an authentic Korean provenance and a formula story that resonates with Japanese consumers, the retail infrastructure and consumer willingness-to-pay are meaningful. If your brand's story is US-centric and Korea is just where you happen to manufacture, Japan will be more work for less lift and the US market is usually the higher-return use of the next twelve months. (For US-first sequencing, our 2026 playbook on how to sell Korean cosmetics in the US as a founder covers the domestic sequence.)
Working with altameet
Altameet is a Manhattan-based Korean ODM consulting practice for US indie K-beauty brands. We work on the sourcing, spec-sheet, and regulatory-readiness end of the launch. That is the layer of decisions that sits between a founder's brand vision and the ODM's factory floor. We do not hold Japanese MAH licenses ourselves; when a Japan launch is on the table, we help founders scope the pathway (cosmetic vs. quasi-drug), pressure-test the current formula against Japan's ingredient rules, and shortlist Japanese MAH partners whose scope matches the brand's SKU count. Reach out at liz@altameet.com or book a slot at altameet.com/contact.
Key takeaways
Japan splits skincare into three regulatory tiers, and the tier is decided by the claim on the box, not the molecule in the bottle. Whitening, wrinkle improvement, acne prevention, and other functional claims trigger the quasi-drug pathway; hydrating and appearance-only language stays in the cosmetic tier. The cosmetic tier is a notification job that can move in weeks; the quasi-drug tier is a pre-market approval that often runs nine to twelve months for streamlined filings and longer for novel actives or novel claims.
The realistic partner stack for an indie K-beauty brand entering Japan is a Japanese MAH holding the marketing authorization and import license, a Korean ODM whose facility is FMR-registered for the intended tier, and a founder who has re-vetted the formula against Japan's positive and negative ingredient lists before Japanese labeling is designed. Founders who treat Japan as a "translate the label and ship" project usually rediscover the tier system after cartons are already printed. Founders who treat Japan as a nine-to-twelve-month regulatory sprint on top of a US launch usually get to shelf without a stall.
By the ALTA MEET editorial team | K-beauty ODM consulting from Manhattan, NYC. Reviewed for accuracy by ALTA MEET's formulation and regulatory consulting team.
Public sources referenced in this piece: PMDA Frequently Asked Questions; PMDA Manufacturing and Marketing Procedures for Quasi-drugs (PDF); PMDA Application for Accreditation of Foreign Manufacturers (PDF)
